RxDoctor Payments Data

Michael Stillabower

Cardiovascular Disease · Newark, DENPI 1548237472

Payments from drug & device makers

What this record shows

Merit Medical Systems Inc accounts for 61.5% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $3,621 and has fallen 99.5% since, to $18 in 2022.

$3,833in general payments, 2019–2025

Across 95 payments — averaging $40.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merit Medical Systems Inc$2K
  • AstraZeneca$382
  • Amgen$211
  • Boehringer Ingelheim$144
  • Amarin Pharma, Inc.$123
  • Sanofi-aventis U.S. LLC$113
  • plus $504 from 11 others
$23,994in research payments, 2019–2025

Across 2 payments — averaging $11,997 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amarin Pharma, Inc.$24K

What the payments were for

  • Travel & lodging$2,26559%
  • Food & beverage$1,56841%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,833 in reported general payments places this provider in the 60th percentile of 104 cardiovascular disease providers in Delaware.

See all cardiovascular disease providers in Delaware →

Other cardiovascular disease in Newark

See the full list for Delaware →

Where these figures come from

Is this you, or does something look wrong? →